AI just got personal: Illumina and Tempus team up to make DNA testing part of every doctor’s visit
Find out how Illumina and Tempus are transforming healthcare with AI-driven genomic tools to advance precision medicine across cancer, cardiology, and more. Read More
Tech and AI stocks plunge as market selloff hits Core Scientific, Vertiv, Root, and more
Tech and AI stocks tumbled on March 26, 2025, as trade tariffs and market uncertainty triggered a selloff. Find out which stocks were the biggest ... Read More
Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have announced a collaboration to integrate Tempus Next, ... Read More
Tempus AI stock soars 14% after FDA approval of xT CDx test
Tempus AI, a leader in healthcare technology, has unveiled its FDA-approved in vitro diagnostic device, xT CDx, marking a pivotal step forward in precision oncology. ... Read More
Tempus AI shakes up precision medicine with $600m acquisition of Ambry Genetics
Tempus AI has taken a significant step in advancing its precision medicine strategy by agreeing to acquire Ambry Genetics in a $600 million deal. This ... Read More